Social and Psychological Long-term Impact of NMDA Receptor Encephalitis

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

NMDA receptor antibody encephalitis is a rare autoimmune neurological disease of the central nervous system with an estimated incidence of 1.5 people per million per year. Patients with anti-NMDAR encephalitis experience an acute phase of the disease characterized by psychosis, memory loss, seizures, autonomic nervous system instability, or coma. Since the discovery of this disease 14 years ago by Prof. Dalmau, the clinical presentation of the acute phase has been well characterized, while the psychosocial impact of the disease remains largely unexplored. Currently, there are few cohort studies of patients that have identified persistent cognitive impairment as a factor impacting remission after the acute phase. Given the scarcity of information concerning the post-acute phase, it is therefore essential to determine the long-term social and psychological outcomes and their daily effects on the social and functional life of this severe disease. This is especially important as the patients are young, with a median age of 21 years, and may face lasting limitations potentially detrimental to their success in professional, educational, or social environments.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• Patients with NMDAR encephalitis

• Age ≥ 18 years old

• Patient affiliated to a social security system

• No opposition from the patient

Locations
Other Locations
France
Centre de référence des syndromes neurologies paranéoplasiques et encéphalites auto-immunes - Hôpital neurologiques Pierre WERTHEIMER
RECRUITING
Bron
Contact Information
Primary
Jérôme JH HONNORAT, MD
jerome.honnorat@chu-lyon.fr
0472357806
Time Frame
Start Date: 2024-12-16
Estimated Completion Date: 2025-12-17
Participants
Target number of participants: 30
Treatments
Anti-NMDAR encephalitis patients.
Patients over 18 years old with NMDAR encephalitis.
Sponsors
Leads: Hospices Civils de Lyon

This content was sourced from clinicaltrials.gov